Any of the following news from Sunesis on Vosaroxin studies could make us a lot of money! 1) Enrollment completed for VALOR, 2) LI-1 interim assessment of Vosaroxin treatment arms, 3) initiation of IST studies, 4) additional patents.
Any additional news on MLN2480 as it relates to Melanoma cohort expansion and the Biogen Idec Program in 2013-2014 will be a further catalyst to propel this stock.
Every day that goes by brings us (the longs) to greater riches! JMHO of course.